13F Holdings
中文EN

XRTX XORTX Therapeutics Inc. IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1729214 · Reporting currency CAD · Fiscal year ends 12/31

Financial factors as of 2021-12-31 (FY2021), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY-28.6%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-18.4%
ROA-13.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets24.0%
Debt / equity0.00x
Current ratio28.78x
Interest coverage—

Cash quality & payout

Operating cash flow / net income3.67x
Accruals ratio36.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: CAD FY2021*2021-12-31FY2020*2020-12-31FY2019*2019-12-31
Income statement
Revenue———
R&D expense853,124277,45539,897
SG&A expense176,0999,51617,344
Pretax income-3.65M-1.40M-565,965
Net income-1.65M-1.28M-629,576
EPS (diluted)———
Balance sheet
Cash & equivalents18.85M171,27158,614
Receivables51,53914,351—
Current assets20.17M2.06M—
Total assets22.04M2.29M—
Current liabilities700,9991.03M—
Total liabilities5.30M1.03M—
Shareholders' equity16.74M1.26M-211,721
Shares outstanding1.79M——
Cash flow statement
Operating cash flow-6.06M-728,401-249,580
Financing cash flow24.46M855,40855,212
Depreciation & amortization17,88220,43919,900
Stock-based compensation499,158293,44326,317

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.